Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

294.65
+0.54000.18%
Post-market: 291.05-3.6048-1.22%16:20 EDT
Volume:489.43K
Turnover:143.64M
Market Cap:8.21B
PE:-21.87
High:299.30
Open:289.98
Low:285.55
Close:294.11
52wk High:356.00
52wk Low:26.70
Shares:27.85M
Float Shares:25.78M
Volume Ratio:0.92
T/O Rate:1.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.4758
EPS(LYR):-13.4758
ROE:-45.83%
ROA:-28.69%
PB:9.35
PE(LYR):-21.87

Loading ...

Praxis Precision Medicines (PRAX) Valuation After FDA-Backed EMBRAVE3 Redesign for Elsunersen

Simply Wall St.
·
Dec 20, 2025

Oppenheimer Adjusts Praxis Precision Medicines PT to $750 From $250, Maintains Outperform Rating

MT Newswires Live
·
Dec 15, 2025

Deutsche Bank Raises Price Target on Praxis Precision Medicines to $313 From $303, Keeps Buy Rating

MT Newswires Live
·
Dec 12, 2025

Praxis Precision Medicines - to File a Nda for Relutrigine in Scn2a and Scn8a Dees in Early 2026

THOMSON REUTERS
·
Dec 12, 2025

Praxis Precision Medicines Reports Relutrigine Shows Significant Seizure Reduction in EMBOLD Study

Reuters
·
Dec 11, 2025

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

GlobeNewswire
·
Dec 11, 2025

BRIEF-Praxis Precision Medicines Announces Alignment With FDA

Reuters
·
Dec 10, 2025

Praxis Precision Medicines Inc: FDA Agreed to Proposed Changes to Embrave3 Trial Design to Be a Single-Arm, Baseline-Controlled Study

THOMSON REUTERS
·
Dec 10, 2025

Praxis Precision Medicines Announces Alignment With FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset Scn2a Developmental and Epileptic Encephalopathy

THOMSON REUTERS
·
Dec 10, 2025

Praxis Precision Medicines Inc: Topline Results From Ongoing Embrave Study (Part a, N=9) Expected in 1H 2026

THOMSON REUTERS
·
Dec 10, 2025

Praxis Precision Medicines Converts EMBRAVE3 Trial to Single-Arm Study for Elsunersen in SCN2A-DEE

Reuters
·
Dec 10, 2025

Praxis Precision Medicines (PRAX) Is Up 34.4% After Dual Neurology Milestones - Has The Bull Case Changed?

Simply Wall St.
·
Dec 09, 2025

Praxis Precision Medicines Inc: Monotherapy Study, Power3, Is on Track to Begin in First Half of 2026

THOMSON REUTERS
·
Dec 09, 2025

Truist Raises Price Target on Praxis Precision Medicines to $500 From $360, Keeps Buy Rating

MT Newswires Live
·
Dec 08, 2025

Praxis Precision Medicines Reports 53% Seizure Reduction With Relutrigine in EMBOLD Study

Reuters
·
Dec 08, 2025

Praxis Precision Medicines Inc : Needham Raises Target Price to $315 From $304

THOMSON REUTERS
·
Dec 08, 2025

Praxis Precision Med Is Maintained at Buy by BTIG

Dow Jones
·
Dec 08, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies

Reuters
·
Dec 06, 2025

Top Midday Gainers

MT Newswires Live
·
Dec 06, 2025

Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next

Benzinga
·
Dec 06, 2025